Direct answer. Mitral stenosis is narrowing of the valve between the left atrium and left ventricle. It restricts filling and can raise pressure upstream in the atrium and lungs. Rheumatic leaflet fusion and degenerative mitral annular calcification are different disease patterns, so the appropriate intervention cannot be chosen from the word stenosis alone. Confidence is high in these distinctions; current guidance is attributed clinical context with explicit financial gaps. NHLBI valve anatomy and types, March2022; Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
- Narrowing and backward leakage are different mitral findings and can coexist.
- Rheumatic fusion and degenerative calcific disease require different anatomical assessment.
- Symptoms can reflect lung congestion or rhythm problems even when ventricular contraction is preserved.
- A balloon commissurotomy is a selected treatment for suitable fused anatomy, not every calcified mitral valve.
- Atrial fibrillation and clot risk require a valve-aware anticoagulation decision, not a borrowed blood thinner.
Evidence summary
| Question | Source role | Conclusion and confidence |
|---|---|---|
| What is restricted? | Public anatomy | Flow from left atrium into left ventricle. High confidence. |
| Are rheumatic and calcific forms identical? | 2025 mechanism guidance | No. Commissural fusion and annular/leaflet calcification differ. |
| Can all cases receive a balloon procedure? | Attributed specialist care | No. Anatomy, clot, leakage and other disease affect suitability. |
| Does good contraction rule out symptoms? | Filling-pressure mechanism | No. Upstream pressure, flow and rhythm also matter. |
Confidence is high in the condition distinctions and need for appropriate assessment. The treatment section attributes clinical guidance; it does not certify the funding of every underlying intervention trial. Independent comparative outcome certainty and a supplement replacement regimen were not established by this focused review. A public institution or independent review cannot make a sponsored original trial financially independent.
What it is
The mitral valve should open during ventricular filling. Stenosis means that opening is restricted. Blood has more difficulty passing from the left atrium to the left ventricle, and pressure can rise in the atrium and pulmonary circulation. Regurgitation is backward leakage during contraction; it is a different problem and may accompany stenosis. NHLBI valve anatomy and types, March2022.
Rheumatic disease can thicken and fuse the valve’s leaflets and affect supporting structures. Degenerative disease can involve calcium around the valve ring extending into the leaflets or adjacent apparatus. Not every calcified ring produces important obstruction. The 2025 guideline treats the rheumatic and degenerative patterns separately because their anatomy, investigation and procedures differ. NHLBI valve disease causes, March2022; Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
Breathlessness, fatigue, reduced capacity and palpitations can occur. Atrial fibrillation and other problems may become part of the presentation. A normal-looking contraction measurement is not enough to dismiss an impaired filling or pressure problem. The symptom history, actual obstruction, pulmonary effects and rhythm need interpretation together. NHLBI valve disease symptoms, March2022; Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
How it works
Restriction increases the resistance between the atrium and ventricle. Heart rate, flow and other loading conditions affect measured gradients and symptoms, so a number cannot be interpreted without context. The atrium can enlarge, lung pressures may rise and associated right-heart or other valve disease can develop. The clinical report should describe these consequences as well as the opening itself. Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
Echocardiography evaluates leaflet movement, opening, severity, supporting anatomy and cardiac effects. In rheumatic disease, the pattern of fusion and calcification helps determine whether a commissurotomy could be suitable. Transoesophageal echo is used for selected procedural planning and to assess atrial clot. In degenerative calcific disease, acoustic shadowing can complicate measurements and selected CT can characterize calcification and procedural anatomy. NHLBI valve disease diagnosis, March2022; Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
Atrial fibrillation may further affect filling and is relevant to thromboembolic risk. The appropriate anticoagulant is not necessarily the same as for atrial fibrillation without significant mitral stenosis. The 2025 guidance specifically distinguishes the rheumatic stenosis setting. A scan result, symptoms and rhythm therefore inform several connected decisions rather than a single valve-only prescription. Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
The evidence-based treatments
Medicines can control congestion, heart rate or associated conditions, but they do not physically separate fused leaflets or remove a calcified obstruction. The clinician should explain whether a treatment targets symptoms, rhythm, clot risk or an intervention indication. Dose and combination depend on the established disease, pressure, kidney function and other circumstances; this is not a personal regimen. NHLBI valve care background, March2022; Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
For selected rheumatic disease with suitable anatomy, percutaneous mitral commissurotomy uses a catheter-based approach to open fused commissures. Important leakage, atrial clot, calcification or other valve/coronary disease can change suitability. Surgery may be considered when a balloon approach is inappropriate or when associated disease also needs treatment. A specialist valve team should explain why the proposed technique fits the specific anatomy. Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
Degenerative mitral stenosis is not generally suitable for commissurotomy because the defining problem is not fused commissures. Surgical and selected transcatheter approaches can be technically difficult and carry important risks, including obstruction of the ventricular outflow tract with some implant strategies. The current guideline acknowledges limited randomized evidence in this setting. A report that calls every procedure “opening the valve” hides material differences in the decision. Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
Clot prevention is a separate, valve-aware decision. Current guidance describes vitamin-K-antagonist anticoagulation in atrial fibrillation with rheumatic stenosis and selected other clot-related circumstances; it does not make all direct oral anticoagulants interchangeable in that setting. Do not self-start aspirin, borrow an anticoagulant or stop a prescribed drug because another person uses a different medicine. The article attributes guidance without independently clearing the entire trial chain. Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
Supplement and lifestyle evidence
Ask for activity advice based on symptoms, obstruction and pulmonary/right-heart findings. Appropriate nutrition, avoiding smoking and management of other health risks support care but cannot establish that fused or calcified tissue has reopened. A fluid or salt plan should be based on documented congestion, medicines and other illnesses rather than a generic restriction sold as valve treatment. NHLBI valve care background, March2022.
No supplement is established here as a treatment for mitral stenosis. “Heart support,” improved vessel relaxation, a changed blood marker and fewer clinical events are different claims. The cited source set does not provide a fully financially screened trial basis for replacing diagnosis or prescribed care. Correcting a clinician-confirmed deficiency is a separate indication; a retail blend is not a diagnostic test or an emergency treatment.
What works and what does not
Useful care describes the narrowing mechanism and distinguishes symptom control from mechanical intervention and clot prevention. It also gives a plan for atrial fibrillation or other associated disease. After commissurotomy or surgery, renewed obstruction, leakage and involvement of other valves can still need review; an initially satisfactory procedure is not permission to abandon follow-up. Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
Ask which outcome is being pursued: symptoms, physiological findings, recurrence, hospital admission or survival. A plan should also say how adverse effects and deterioration will be recognized. Personal stories and before-and-after readings cannot separate treatment effects from the natural course, other medicines or selection of patients. Manufacturer or materially conflicted outcome claims do not determine this article’s independent verdict.
Risks and side effects
Severe breathing difficulty, collapse, new concerning chest pain or sudden major deterioration needs emergency help. New stroke-like symptoms are an emergency. Worsening breathlessness, important palpitations or fainting should not wait for a routine valve review; urgency depends on current symptoms rather than an old scan label. NHS current national heart valve disease education; NHLBI valve care background, March2022.
Diuretics and rate medicines can affect pressure, kidney function, electrolytes and heart rate; anticoagulants can cause bleeding. Balloon, surgical or catheter procedures can cause embolic events, bleeding, valve injury or important residual leakage/obstruction, with risks varying by anatomy and method. A consent discussion should address the relevant alternatives and subsequent follow-up. NHLBI valve care background, March2022; Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
Important interactions
Review rate-control medicines, diuretics, anticoagulants, anti-inflammatory pain products and supplements together. Some products alter bleeding or drug exposure and should be checked by the prescribing team. Anticoagulation choices must account for the stenosis rather than being copied from a general atrial-fibrillation advertisement or another patient. Do not change medicines before pregnancy or a procedure without the responsible service. NHLBI valve disease and pregnancy, March2022; Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
Bring prescription medicines, non-prescription products, recreational drugs and supplements to the same medication review. Product names alone may hide several active ingredients. The prescriber or pharmacist should check the exact combination and kidney function, rather than treating “natural” as a safety category. Never add a second person’s rescue medicine or stop an important prescribed medicine because an internet list mentions a possible interaction.
Who needs assessment
Ask whether the disease is rheumatic, degenerative calcific or another pattern, how severity and pulmonary effects were established, and whether atrial fibrillation, clot or other valve disease is present. A planned intervention needs anatomical suitability and procedural-risk assessment. A home exercise challenge, pulse reading or one report number cannot safely replace that evaluation. NHLBI valve disease diagnosis, March2022; Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
Pregnancy planning, a previous valve intervention, kidney disease and anticoagulant use deserve specific review. The current status of the valve matters more than an old diagnostic label. Children with congenital disease need an age-appropriate specialist pathway rather than an adult intervention rule. NHLBI valve disease and pregnancy, March2022.
Clinician-led use and follow-up
Ask when valve opening, gradients, leakage, pulmonary effects and rhythm will be reassessed and which symptoms prompt earlier contact. Pregnancy planning, non-cardiac surgery and a change in anticoagulation warrant specific review. There is no personal dose, procedural threshold or fixed monitoring interval here; the treating team should provide an indication-specific written plan. Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
This guide gives no personal drug, device or supplement dose. The appropriate plan depends on the established diagnosis, current stability, other illnesses and local services. Ask for a written explanation of the treatment purpose, warning signs, review schedule and contact route for side effects. Clinical monitoring and informed consent should accompany any change; study exposures are not prescriptions.
Animal and in-vitro evidence
Laboratory work on valve calcification, connective tissue or blood-flow mechanics can help investigate a mechanism. It cannot determine a safe human supplement dose, establish that a calcified valve will reopen, or select an implant for an individual. An animal or cell finding does not replace a clinical assessment of anatomy, severity and complications. No animal or in-vitro result contributes to this guide’s independent clinical verdict.
Funding and source roles
Who paid for the evidence?
Follow named sources to the funding and relationships disclosed in this article. Numbered article disclosures preserve notes where a source is not identified. A public or university name alone does not establish independence.
View 16 more funding disclosures
This graphic reorganizes the article's disclosures; it is not a new financial audit or independence classification. Highlighted notes show different funding relationships where available. Review funding is separate from underlying trial funding. Disclosure is not proof of falsehood, and no declared conflict is not proof of complete independence.
Financial interests include echocardiography and advanced imaging, valve implants, surgical and catheter services, medicines and marketed supplements. Valve-device manufacturers and professional societies can have relevant financial relationships even when the document itself reports no direct industry-development funding. Those routes and unresolved author/trial chains are shown below; no manufacturer or materially conflicted outcome claim establishes this guide’s independent verdict.
The condition has no corporate owner. Medicines, diagnostics, devices, procedures and marketed supplements create different revenue incentives. This describes financial interests rather than misconduct. Funding tier evaluates proximity to the subject; A–D credibility assesses transparency, accuracy incentives and remaining uncertainty. An unresolved link stays unresolved, and a provisional public-information label does not clear the trials behind it.
| Source | Funding / backers | Country / jurisdiction | Independence | Credibility / incentives / gaps |
|---|---|---|---|---|
| NHLBI valve anatomy and types, March2022 | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | B provisional. Public accountability and educational review favour accuracy; institutional priorities, simplification, dated wording and untraced trial ties remain. Role: Dated public anatomy and distinctions between stenosis, regurgitation and prolapse. |
| NHLBI valve disease causes, March2022 | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | B provisional. Public accountability and educational review favour accuracy; institutional priorities, simplification, dated wording and untraced trial ties remain. Role: Dated public inherited and acquired contributor education. |
| NHLBI valve disease symptoms, March2022 | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | B provisional. Public accountability and educational review favour accuracy; institutional priorities, simplification, dated wording and untraced trial ties remain. Role: Public symptom education; symptoms do not establish severity. |
| NHLBI valve disease diagnosis, March2022 | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | B provisional. Public accountability and educational review favour accuracy; institutional priorities, simplification, dated wording and untraced trial ties remain. Role: Clinical investigation background; no self-diagnostic thresholds. |
| NHLBI valve care background, March2022 | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | B provisional. Public accountability and educational review favour accuracy; institutional priorities, simplification, dated wording and untraced trial ties remain. Role: Dated public procedure/adverse-effect background; oversimplified tissue-valve anticoagulation wording not reproduced. |
| NHS current national heart valve disease education | DHSC funds the national NHS website; its policy states no advertising or corporate sponsorship. Named authors, page-level budget and full underlying trial conflicts unresolved. | United Kingdom; England national public-information service. Other jurisdictions have different services. | Tier 1 public education provisional; not a clearance of original studies. | B provisional. Public-service remit and editorial checks support accuracy; simplification, service priorities and incomplete trial-finance tracing limit inference. Role: January 2025 national condition and emergency education; broad prolapse wording not reproduced. |
| Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF | The original guideline states document development was financed entirely by ESC and EACTS without healthcare-industry involvement. ESC institutional revenues nevertheless include life-science and medtech partnerships; EACTS discloses industry/charity grants and an Edwards Lifesciences Foundation partnership. That separate route does not prove Edwards funded this guideline. The official 2025 author declaration report returned 403 and was not read. Article allocation, individual author independence and original device/drug trial chains remain unresolved. | France: ESC, Sophia Antipolis. United Kingdom: EACTS, Windsor, registered England and Wales; OUP publisher UK. International writing panel. The unchanged original EJCTS PDF mirror is hosted by MATCVS, Malaysia; it does not change the document author or funding origin. Edwards corporate headquarters Irvine, California, US; specific supplied-device manufacturing origin unresolved. | Tier 2 documented society industry routes, with unresolved author chain; independent efficacy excluded. | C provisional. Original 109-page guideline and August 2026 correction checked. Detailed methodology, specialist review and explicit evidence grades aid attributed clinical use; society commercial routes, inaccessible author declarations and uncleared original-trial finances prevent a clean independent outcome verdict. Role: Current 2025 specialist care context with August2026 correction checked; C provisional, not independent efficacy. |
| NHLBI valve disease and pregnancy, March2022 | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | B provisional. Public accountability and educational review favour accuracy; institutional priorities, simplification, dated wording and untraced trial ties remain. Role: Pregnancy planning in stenotic valve disease. |
| NHLBI valve disease definitions, March2022 | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 1 public education provisionally; donation route and page-specific chain unresolved. | B provisional. Public accountability and educational review favour accuracy; institutional priorities, simplification, dated wording and untraced trial ties remain. Role: Additional original linked in condition-specific education or follow-up. |
| NHLBI budget | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 3 institutional financial self-disclosure. | B provisional. Direct public financial policy, with legal accountability; actual gift donors and allocations not audited. Financial provenance only. |
| NHLBI Gift Fund | US federal appropriations; separate Gift Fund accepts donations and bequests, including support for public health information. Budget route; Gift authority. Actual donors, page allocation and underlying trial finances unresolved. | United States; NIH/NHLBI, Bethesda, Maryland; federal jurisdiction. | Tier 3 institutional financial self-disclosure. | B provisional. Direct public financial policy, with legal accountability; actual gift donors and allocations not audited. Financial provenance only. |
| NHS national website funding policy | DHSC funds the national NHS website; its policy states no advertising or corporate sponsorship. Named authors, page-level budget and full underlying trial conflicts unresolved. | United Kingdom; England national public-information service. Other jurisdictions have different services. | Tier 3 editorial and financial self-disclosure. | B provisional. Explicit funding policy; actual individual declarations and implementation not audited. Financial provenance only. |
| ESC funding and revenue model | ESC directly reports life-science and medtech partnership income alongside memberships, congresses, publishing and education. Its July 2026 policy manages industry remuneration and other interests; reporting a policy is not proof that all bias is removed. | France; ESC European Heart House, Sophia Antipolis; multinational professional society. | Tier 3 institutional self-disclosure; financially interested in its own governance description. | B provisional for stated revenue routes; C where relied on to certify its own clinical independence. Financial transparency supports checking; actual amounts, implementation and document allocations not audited. Financial provenance only. |
| ESC conflict management policy | ESC directly reports life-science and medtech partnership income alongside memberships, congresses, publishing and education. Its July 2026 policy manages industry remuneration and other interests; reporting a policy is not proof that all bias is removed. | France; ESC European Heart House, Sophia Antipolis; multinational professional society. | Tier 3 institutional self-disclosure; financially interested in its own governance description. | B provisional for stated revenue routes; C where relied on to certify its own clinical independence. Financial transparency supports checking; actual amounts, implementation and document allocations not audited. Financial provenance only. |
| EACTS current industry/charity grant and Edwards Foundation relationship | EACTS explicitly offers industry/charity-sponsored outreach grants and names Edwards Lifesciences Foundation for Every Heartbeat Matters; a separate industry-sponsorship contact is provided. Edwards confirms funding, product donations and matching-gift routes. EACTS annual revenue amounts, complete donor list, guideline allocation and individual author finances were not fully traced. This is a documented institutional relationship, not evidence that Edwards directly financed the valve guideline. | United Kingdom; EACTS House, Windsor, registered company and charity in England and Wales. Edwards corporate headquarters Irvine, California, United States; global manufacturing locations differ from grant or guideline jurisdiction. | Tier 3 institutional financial self-disclosure; society has a stake in its own governance description. | B provisional for documented relationships and registered contact; C if used to certify clinical independence. Direct named support improves transparency; amounts, contract terms, full donor and page/author chains remain unresolved. Financial provenance only. |
| EACTS industry sponsorship route | EACTS explicitly offers industry/charity-sponsored outreach grants and names Edwards Lifesciences Foundation for Every Heartbeat Matters; a separate industry-sponsorship contact is provided. Edwards confirms funding, product donations and matching-gift routes. EACTS annual revenue amounts, complete donor list, guideline allocation and individual author finances were not fully traced. This is a documented institutional relationship, not evidence that Edwards directly financed the valve guideline. | United Kingdom; EACTS House, Windsor, registered company and charity in England and Wales. Edwards corporate headquarters Irvine, California, United States; global manufacturing locations differ from grant or guideline jurisdiction. | Tier 3 institutional financial self-disclosure; society has a stake in its own governance description. | B provisional for documented relationships and registered contact; C if used to certify clinical independence. Direct named support improves transparency; amounts, contract terms, full donor and page/author chains remain unresolved. Financial provenance only. |
| EACTS registered jurisdiction and Windsor contact | EACTS explicitly offers industry/charity-sponsored outreach grants and names Edwards Lifesciences Foundation for Every Heartbeat Matters; a separate industry-sponsorship contact is provided. Edwards confirms funding, product donations and matching-gift routes. EACTS annual revenue amounts, complete donor list, guideline allocation and individual author finances were not fully traced. This is a documented institutional relationship, not evidence that Edwards directly financed the valve guideline. | United Kingdom; EACTS House, Windsor, registered company and charity in England and Wales. Edwards corporate headquarters Irvine, California, United States; global manufacturing locations differ from grant or guideline jurisdiction. | Tier 3 institutional financial self-disclosure; society has a stake in its own governance description. | B provisional for documented relationships and registered contact; C if used to certify clinical independence. Direct named support improves transparency; amounts, contract terms, full donor and page/author chains remain unresolved. Financial provenance only. |
| Edwards corporate/foundation funding and technology-donation routes | Edwards Lifesciences corporate/foundation self-disclosure. It describes charitable funding, technology donations, employee matching and annual recipients. Corporate device sales and reputation create a direct interest; no corporate clinical outcome claim is used as independent evidence. Foundation-wide donors, grant contract terms and specific product provenance were not audited. | United States; Edwards Lifesciences corporate global headquarters Irvine, California. The opened location page names US manufacturing and says manufacturing is multinational; a headquarters is not the origin of every implant. | Tier 4 maker-associated corporate/foundation self-disclosure; clinical outcome claims excluded. | D for clinical promotion; provisional B only for explicit self-reported addresses and funding routes cross-checked with EACTS. Commercial and reputational incentives remain. Financial provenance only. |
| Edwards global headquarters and manufacturing-location disclosure | Edwards Lifesciences corporate/foundation self-disclosure. It describes charitable funding, technology donations, employee matching and annual recipients. Corporate device sales and reputation create a direct interest; no corporate clinical outcome claim is used as independent evidence. Foundation-wide donors, grant contract terms and specific product provenance were not audited. | United States; Edwards Lifesciences corporate global headquarters Irvine, California. The opened location page names US manufacturing and says manufacturing is multinational; a headquarters is not the origin of every implant. | Tier 4 maker-associated corporate/foundation self-disclosure; clinical outcome claims excluded. | D for clinical promotion; provisional B only for explicit self-reported addresses and funding routes cross-checked with EACTS. Commercial and reputational incentives remain. Financial provenance only. |
Frequently asked questions
Is a calcified mitral ring the same as stenosis? No. Calcification may or may not produce important obstruction or leakage, so function must be assessed. Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
Can every narrowed valve be treated with a balloon? No. The cause, fused anatomy, clot, leakage and accompanying disease determine suitability. Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
Does preserved ejection fraction rule out serious disease? No. Filling, upstream pressures, rhythm and symptoms are separate parts of the assessment. Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF.
Is pregnancy planning relevant? Yes. Narrowed valves can make pregnancy higher risk and may require assessment or treatment beforehand; the medicines and delivery plan need specialist review. NHLBI valve disease and pregnancy, March2022.
Sources and funding notes
- NHLBI valve anatomy and types, March2022 — Dated public anatomy and distinctions between stenosis, regurgitation and prolapse.
- NHLBI valve disease causes, March2022 — Dated public inherited and acquired contributor education.
- NHLBI valve disease symptoms, March2022 — Public symptom education; symptoms do not establish severity.
- NHLBI valve disease diagnosis, March2022 — Clinical investigation background; no self-diagnostic thresholds.
- NHLBI valve care background, March2022 — Dated public procedure/adverse-effect background; oversimplified tissue-valve anticoagulation wording not reproduced.
- NHS current national heart valve disease education — January 2025 national condition and emergency education; broad prolapse wording not reproduced.
- Original 2025 ESC/EACTS valve guideline, society-hosted OUP PDF — Current 2025 specialist care context with August2026 correction checked; C provisional, not independent efficacy.
- NHLBI valve disease and pregnancy, March2022 — Pregnancy planning in stenotic valve disease.
- NHLBI valve disease definitions, March2022 — Additional original linked in condition-specific education or follow-up.
- NHLBI budget — Financial provenance only.
- NHLBI Gift Fund — Financial provenance only.
- NHS national website funding policy — Financial provenance only.
- ESC funding and revenue model — Financial provenance only.
- ESC conflict management policy — Financial provenance only.
- EACTS current industry/charity grant and Edwards Foundation relationship — Financial provenance only.
- EACTS industry sponsorship route — Financial provenance only.
- EACTS registered jurisdiction and Windsor contact — Financial provenance only.
- Edwards corporate/foundation funding and technology-donation routes — Financial provenance only.
- Edwards global headquarters and manufacturing-location disclosure — Financial provenance only.
Original clinical pages and their relevant financial disclosures were opened. The original 109-page 2025 ESC/EACTS valve guideline was read from MATCVS’s unchanged EJCTS/OUP PDF mirror, with its title, authors and DOI verified. The official August 6, 2026 correction was opened separately. The official author-declaration PDF returned 403 and was not read. Actual ESC, EACTS and Edwards financial-route disclosures were checked; separate institutional industry support does not establish direct industry financing of this document. Individual author and original-trial financial chains remain unresolved; clinical recommendations are C-provisional context. Clinical sources concentrate on US and English public education plus European professional guidance. This limits jurisdictional breadth: referral, implant availability and treatment systems vary, and no global access claim is inferred. Guidance, classification, emergency education and independent efficacy are distinct source roles. A full systematic review, complete society donor audit and author-by-author clearance of original treatment trials were not completed.
Last reviewed: October 4, 2026. Educational information, not a diagnosis or personal treatment plan. Use your local emergency service for an emergency.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.